Meridian Bioscience Acquires Magellan Diagnostics, Inc.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Canaccord Genuity Remains Sidelined Following Meridian Bioscience's (VIVO) Announced Magellan Diagnostics Acquisition
March 28, 2016 10:17 AM EDTCanaccord Genuity reiterated a Hold rating on Meridian Biosciences (NASDAQ: VIVO), and raised the price target to $19.00 (from $18.00), following the company's announced acquisition of Magellan Diagnostics. The acquisition marks VIVO's first material acquisition in nearly 6 years. Boston-based Magellan Diagnostics offers the only rapid (3-minute),... More
